A. Ahmadi
Urmia University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Ahmadi.
Human & Experimental Toxicology | 2008
M.A. Rezvanfar; Rajab Ali Sadrkhanlou; A. Ahmadi; Azadeh Mohammadirad; Alinazar Salehnia; Mohammad Abdollahi
Cyclophosphamide (CP) as an anticancer alkylating agent has been known as a male reproductive tract toxicant. The aim of this study was to examine whether Satureja khuzestanica essential oil (SKEO) as an established herbal antioxidant, might protect tract rat reproductive system from toxicity of CP. To reach this aim, total antioxidant power (TAP) and lipid peroxidation (LPO) in testis and plasma, blood levels of sex hormones, sperm characteristics, DNA integrity and chromatin quality, and fertility in male rats were tested. Histopathological analysis of testes and epididymides and staining of mast cells were performed for assessment of spermatogenic disorders. CP (6 mg/kg/day) and SKEO (225 mg/kg/day) were administered alone or in combination by gavage for 28 days. In the CP-exposed rats, testicular and plasma LPO increased, TAP decreased, plasma testosterone diminished, and both spermatogenesis and fertility were impaired. In CP-treated rats, a decrease in sperm quality was associated with increased DNA damage and decreased chromatin quality. Coadministration of SKEO significantly improved CP-induced changes in plasma testosterone, sperm quality, spermatogenesis and fertility, toxic stress, and DNA damage. It is concluded that CP-induced toxic effects on androgenesis and spermatogenesis is mediated by free radicals. SKEO protects reproductive system from toxicity of CP through its antioxidant potential and androgenic activity.
Theriogenology | 2012
M.A. Rezvanfar; A. Ahmadi; H.A. Shojaei-Saadi; Maryam Baeeri; Mohammad Abdollahi
The objective was to evaluate ovarian functionality and oxidative response in hyperandrogenism-induced polycystic ovary (PCO) and the protective effects of immunomodulator drug (IMOD), an electromagnetically-treated, selenium-based, herbal medicine. Daily oral administration of letrozole (1 mg/kg) for 21 consecutive days induced ovarian cysts in female rats. An effective dose of IMOD (30 mg/kg per day) was given intraperitoneally for 21 days. Biomarkers of ovarian function, serum concentrations of estradiol, progesterone, testosterone, and ovarian prostaglandin-E (PGE), were analyzed. To determine the role of oxidative stress (OS) in hyperandrogenism-induced PCO, concentrations of cellular lipid peroxidation (LPO), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), peroxynitrite (ONOO), and tumor necrosis factor (TNF)-α as a marker of inflammation and apoptosis were measured in serum and ovaries. Letrozole-induced PCO resulted in significant increases in concentrations of lipid peroxidation and peroxynitrite in serum and ovary, but significantly decreased superoxide dismutase, catalase, and glutathione peroxidase. Serum concentrations of testosterone and TNF-α, and ovarian prostaglandin-E were increased (P < 0.001) in animals with cysts versus control, whereas estradiol and progesterone were decreased (P < 0.01 and P < 0.001, respectively). When compared with controls, letrozole induced irregular cycles and PCO characterized by a high incidence of subcapsular ovarian cysts with a diminished granulosa cell layer, luteinized granulosa cells in the cyst wall, significantly more atretic preantral and antral follicles, and absence of CL. There were almost no intact primary, secondary, and tertiary follicles in PCO rats. All end points assessed were significantly improved by IMOD and reached close to normal levels. In conclusion, the present study provided evidence that toxic free radicals and TNF-α were involved in the pathogenesis of PCO; furthermore, IMOD prevented ovarian histopathologic, endocrine, and biochemical alterations induced by hyperandrogenism.
Human & Experimental Toxicology | 2012
M.A. Rezvanfar; A. Ahmadi; Ha Shojaei Saadi; Maryam Baeeri; Mohammad Abdollahi
This study aimed to investigate the possible relationship between ovarian functionality and the oxidative response during cystogenesis induced by hyperandrogenization with letrozole and examine protective effect of the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, pioglitazone (PIO), in polycystic ovary (PCO). Ovarian cysts were induced by oral administration of letrozol (1 mg/kg/day) for 21 consecutive days in the female rats. Effective dose of PIO (20 mg/kg/day) was administrated orally for 21 days. Serum estradiol (E), progesterone (P), testosterone (T), and the ovarian immunomodulator prostaglandin E (PGE) were analyzed as biomarkers of ovarian function. To determine the role of oxidative stress in PCO, the level of cellular lipid peroxidation (LPO), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and peroxynitrite (ONOO), and tumor necrosis factor alpha (TNF-α) as a marker of inflammation and apoptosis were measured in serum and the ovaries. Letrozole-induced PCO in rats exhibited a significant increase in LPO and ONOO in serum and ovary while significantly decreased serum and ovarian SOD, CAT, and GPx. Serum T and TNF-α, and ovarian PGE were increased in animals with cysts compared with healthy controls, while E and P diminished. When compared to control group, letrozole-treated group showed irregular sexual cycles, polycystic ovaries characterized by high incidence of sub-capsular ovarian cyst with diminished or scant granulosa cell layer, increased number of atretic pre-antral and antral follicles and absence of corpus luteum. There were almost no primary, secondary, and tertiary follicles observed in PCO rats. All measured parameters were improved by PIO and reached close to normal levels. The present study further supports the role of oxidative/nitrosative stress and infiammatory responses in the pathogenesis of letrozole-induced hyperandrogenic PCO rats. Results indicate that PIO is able to exert direct antioxidative and anti-inflammatory effects on the endocrine, biochemical, and pathological alterations independent of its possible effects mediated via increased insulin sensitivity in hyperandrogenized PCO.
Experimental and Toxicologic Pathology | 2010
Mohammad Amin Rezvanfar; Amir Abbas Farshid; Rajab Ali Sadrkhanlou; A. Ahmadi; Alinazar Salehnia; Mohammad Abdollahi
Cyclophosphamide (CP) as a widely used antineoplastic drug causes hemorrhagic cystitis (HC) mainly via induction of oxidative stress. Regarding established antioxidant potential of Satureja khuzestanica (Lamiaceae) essential oil (SKEO), we aimed to investigate its protective effects in a subchronic rat model of CP-induced HC. CP (6mg/kg/day) and SKEO (225mg/kg/day) were administered alone or in combination by gavage for 28 days. Histopathological changes were investigated by light microscopy. Plasma samples were assayed for lipid peroxidation and total antioxidant power as biomarkers of toxic stress. In the CP-treated animals, irregular mucus layer, severe hemorrhage and edema, infiltration of inflammatory cells, and accumulation of mast cells were observed. In the CP+SKEO group, a relatively normal urothelial topography with decreased number of mucosal mast cells and inflammatory cells were observed. Increased lipid peroxidation along with decreased total antioxidant capacity resulting from CP treatment was significantly recovered by SKEO co-treatment. It is concluded that SKEO protects rats from CP-induced HC by reduction of free radical-induced toxic stress. It is strongly recommended to examine SKEO in the clinic to approve its benefit in patients undertaking CP.
Tehran University of Medical Sciences | 2010
A. Mahmoodpoor; K. Eslami; Mojtaba Mojtahedzadeh; Atabak Najafi; A. Ahmadi; A. Dehnadi-Moghadam; A. Mohammadirad; Maryam Baeeri; Mohammad Abdollahi
DARU | 2010
Hadi Hamishehkar; Mohammad Taghi Beigmohammadi; Mohammad Abdollahi; A. Ahmadi; A. Mahmoodpour; M.R. Mirjalili; R. Abrishami; Mohammad Reza Khoshayand; K. Eslami; M. Kanani; Maryam Baeeri; Mojtaba Mojtahedzadeh
Tehran University of Medical Sciences | 2010
R. Abrishami; A. Ahmadi; Mohammad Abdollahi; A. Moosivand; Hossein Khalili; Atabak Najafi; Kheirollah Gholami; Hadi Hamishehkar; A. Peivandi Yazdi; Mojtaba Mojtahedzadeh
European Review for Medical and Pharmacological Sciences | 2013
Hendoui N; Mohammad Taghi Beigmohammadi; Ata Mahmoodpoor; A. Ahmadi; Mohammad Abdollahi; Hasanpour M; Hadi F; Zahra Khazaeipour; Sarah Mousavi; Mojtaba Mojtahedzadeh
Archive | 2009
Atabak Najafi; Mojtaba Mojtahedzadeh; Ata Mahmoodpoor; Mostafa Aghamohammadi; A. Ahmadi; Sheida Nahreini; Marzieh Pazuki; Mohammad Reza Khajavi; Mohammad Abdollahi
European Review for Medical and Pharmacological Sciences | 2011
Sarah Mousavi; Mohammad Abdollahi; A. Ahmadi; Atabak Najafi; Pazouki M; Molouk Hadjibabaie; Ziaee S; Hadi Hamishehkar; Abbas Kebriaeezadeh; Mojtaba Mojtahedzadeh